Previous studies have shown that acquired resistance to BRAF-directed therapy in BRAF V600E colorectal cancer patients is often caused by genomic alterations (e.g., RAS mutations) that lead to reactivation of MAPK signaling [6–9]. The gene discussed is BRAF; the disease is colorectal cancer.